The Cancer Drug Development Forum (CDDF) is pleased to present our live webinar series on “AI and Big Data in Cancer Drug Development.” This series is designed to explore the transformative impact of artificial intelligence and big data on oncology. Featuring leading experts, the webinars will delve into the latest advancements and applications of AI in cancer drug discovery, development, and regulatory processes. Join us to uncover how these cutting-edge technologies are accelerating innovation, improving efficiency, and enhancing outcomes in oncology drug development.
First Webinar: An introduction to the use of AI in cancer drug development and regulatory considerations
The inaugural webinar in our series, “An introduction to the use of AI in cancer drug development and regulatory considerations“ will take place on 29 October 2024 at 17:00 CET. This webinar will feature a lecture given by Dr Katrin Rupalla (Johnson & Johnson) and will be followed by a panel discussion moderated by Prof. Axel Glasmacher (CDDF) and Prof. Jaap Verweij (CDDF).
WEBINAR OUTLINE
AI is transforming drug development by enhancing clinical operations, regulatory processes, and study design. Its specific applications in cancer research are particularly impactful. In oncology, AI helps identify biomarkers and genetic mutations associated with different types of cancer, enabling more precise patient stratification and personalized treatment approaches. AI-driven image analysis also enhances the detection and monitoring of tumors through advanced imaging techniques, providing more accurate assessments of tumor progression and treatment response.
Additionally, AI assists in predicting patient outcomes and treatment responses by analyzing clinical data, genetic information, and past case studies. This predictive capability is crucial when considering individual cancer patients for participation in specific clinical trials. Furthermore, AI can optimize the design of cancer clinical trials by identifying the most promising drug combinations or therapeutic strategies. This not only improves the likelihood of trial success but also accelerates the development of new cancer therapies.
In this webinar, we will explore the potential applications of AI in cancer drug development, highlight specific use cases, and discuss regulatory requirements for its implementation.
Agenda: (CET time zone)
17:00 – 17:05 Introduction – Prof. Axel Glasmacher (CDDF, DE)
17:05 – 17:30 Lecture by Dr Katrin Rupalla (Johnson & Johnson, NL)
17:30 – 18:00 Panel discussion – moderated by Prof. Jaap Verweij (CDDF, NL) and Prof. Axel Glasmacher (CDDF, DE)
Dr Katrin Rupalla
Katrin Rupalla has extensive experience in drug development and held various leadership roles in the Pharma and biotech industry. She currently serves as the Global Head of Regulatory Affairs at J&J Innovative Medicines, USA.
Prior to joining J&J in 2023, she was an independent board member where she was responsible for governance and strategic direction of 4D Pharma, Ambrx and Zversa, incl. oversight of three IPO and SPAC acquisitions. She also is one of the Founders and previous CEO of Ymmunobio, Switzerland a preclinical stage biotech company.
Previous senior leadership positions include Senior Vice President, Global Head Regulatory Affairs & R&D Quality, at Lundbeck SA, DK and Vice President Global Head Oncology Regulatory Science, Vice President Head China Development, and Vice President EU Regulatory Science at BMS where she led large regulatory and R&D teams.
She obtained her degree in pharmacy and her PhD in CNS Pharmacology at the Philipps University Marburg, Germany. In addition, she has an MBA from Jones International University, USA and a NED Diploma from Financial Times